FDA authorizes oral rinse-and-spit test for COVID-19

coronavirus test tubes
A COVID-19 diagnostic test was previously granted a green light by the agency in mid-July for use with nasopharyngeal, nasal and oral swabs. (Getty/RossHelen)

The FDA has expanded an emergency authorization of a COVID-19 diagnostic to allow it to test samples gathered by rinsing a person’s mouth with simple saline.

By swishing and gargling a small amount of solution for 30 seconds and then spitting it into a funnel and vial, the test both eliminates the need for a nasal swab and assists people who may have trouble providing sufficient amounts of saliva for a direct test. 

In addition, the samples can be stored for up to 72 hours at room temperature before processing. The prescription-only OraRisk molecular diagnostic test, developed by Access Genetics and its subsidiary OralDNA Labs, is designed to be administered by a healthcare professional.

RELATED: United Airlines to offer COVID-19 testing, starting from SFO to Hawaii

The same test was previously granted a green light by the agency in mid-July for use with nasopharyngeal, nasal and oral swabs.

"Oral rinse collection will be a game-changer for COVID testing," OralDNA CEO George Hoedeman said in a statement. "A 30-second convenient collection without a nasal swab will improve patient comfort, minimize exposure risk to frontline healthcare professionals, shorten collection time, and avoid supply chain bottlenecks.”

Suggested Articles

Medtronic has expanded its portfolio aimed at improving the safety of head and neck surgeries, with a new acquisition and an FDA clearance.

By casting a broad, digital net to pick up the signs of coronavirus outbreaks, researchers hope to build an early warning system from wearable tech.

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.